Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities (Tables)

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2018

Schedule Of Cost And Fair Value Of Marketable Securities


		March 31, 2018
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Commercial Paper	$	1,247,021	$	-	$	(1,758)	$	1,245,263
Corporate Bonds		13,726,899		-		(87,618)		13,639,281
Total Marketable Securities	$	14,973,920	$	-	$	(89,376)	$	14,884,544

		December 31, 2017
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Commercial Paper		3,241,005		-		(2,505)		3,238,500
Corporate Bonds		14,747,822		-		(54,381)		14,693,441
Total Marketable Securities	$	17,988,827	$	-	$	(56,886)	$	17,931,941

Schedule Of Cost And Fair Value By Contractual Maturity


Maturity	Cost Basis		Fair Value
Less than 1 year	$	11,978,760	$	11,921,344
1 to 5 years		2,995,160		2,963,200
Total Marketable Securities	$	14,973,920	$	14,884,544

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details